Copyright: ©Author(s) 2026.
World J Transplant. Jun 18, 2026; 16(2): 118012
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118012
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118012
Table 3 Coronavirus disease 2019 vaccines (adult)-recommended use and clinical notes in chronic liver disease/Liver transplantation
| Vaccine (brand) | Recommended adult use | Clinical notes in CLD/LT |
| Pfizer–BioNTech (Comirnaty®; mRNA) | Updated/seasonal dose(s) per national guidance for adults | Preferred platform for most CLD/LT due to strong effectiveness and safety experience. Responses may be attenuated and additional boosters often needed |
| Moderna (Spikevax®; mRNA) | ||
| AstraZeneca (Vaxzevria®; viral vector) | Where available/used: 2-dose primary series per local policy; boosters typically with an updated vaccine | Generally not first-line for immunocompromised patients. Heterologous boosting with mRNA may improve breadth of responses |
- Citation: Papic N, Kosuta I, Ljubas D, Vrsaljko N, Sesa V, Domislovic V, Ahsan S, Mrzljak A. Not just another shot: Tailoring vaccination in the era of modern liver transplantation. World J Transplant 2026; 16(2): 118012
- URL: https://www.wjgnet.com/2220-3230/full/v16/i2/118012.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i2.118012